LETTER TO THE EDITOR
Recent changes in the frequency of use of apheresis and biological drugs in the treatment of neuromyelitis optica spectrum disorders
Katsuichi Miyamoto,
Corresponding Author
Katsuichi Miyamoto
Department of Neurology, Wakayama Medical University, Wakayama, Japan
Correspondence
Katsuichi Miyamoto, Department of Neurology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8510, Japan.
Email: [email protected]
Search for more papers by this author Yoshiaki Nakayama,
Yoshiaki Nakayama
Department of Neurology, Wakayama Medical University, Wakayama, Japan
Search for more papers by this author Hidefumi Ito,
Hidefumi Ito
Department of Neurology, Wakayama Medical University, Wakayama, Japan
Search for more papers by this author
Katsuichi Miyamoto,
Corresponding Author
Katsuichi Miyamoto
Department of Neurology, Wakayama Medical University, Wakayama, Japan
Correspondence
Katsuichi Miyamoto, Department of Neurology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8510, Japan.
Email: [email protected]
Search for more papers by this author Yoshiaki Nakayama,
Yoshiaki Nakayama
Department of Neurology, Wakayama Medical University, Wakayama, Japan
Search for more papers by this author Hidefumi Ito,
Hidefumi Ito
Department of Neurology, Wakayama Medical University, Wakayama, Japan
Search for more papers by this author
First published: 24 February 2023
No abstract is available for this article.
REFERENCES
- 1Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019; 32: 385–94.
- 2Holmøy T, Høglund RA, Illes Z, Myhr KM, Torkildsen Ø. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol. 2020; 268: 4522–36. https://doi.org/10.1007/s00415-020-10235-5
- 3Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85: 177–89.
- 4Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial. 2009; 13: 505–8.
